This site is for informational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult your healthcare provider.
HIghly MetAstatic Life Prolonging Therapy-Resistant Prostate Cancer: Role of Stereotactic Radiotherapy for Bone and Lymph Node Metastases (HIMARS) | MicrobiomeTrials
← Back to trials NCT06978296
HIghly MetAstatic Life Prolonging Therapy-Resistant Prostate Cancer: Role of Stereotactic Radiotherapy for Bone and Lymph Node Metastases (HIMARS) Recruiting NA INTERVENTIONAL
Read the full scientific description See full eligibility requirements Trial Details Start: 2026-06-01Est. Completion: 2028-05-01
Enrollment target: 18 participantsLocations ICO, Saint-Herblain, France Other microbiome trials you might be interested in Metastatic Breast Cancer Metastatic Prostate Cancer GRPR-Targeted Molecular Imaging Theranostic Radiopharmaceuticals Cancer Active Cancer Theranostic Radiopharmaceutical
This is an open-label, first-in-human, exploratory Phase 0 study evaluating the safety and diagnostic imaging performanc…
Perth, Australia Est. completion May 30, 2028
Gastro-Oesophageal Cancer
To determine if the regorafenib and nivolumab combination (RegoNivo) improves overall survival compared with current sta…
Scottsdale, United States Completed Jan 14, 2025
Oligometastatic Prostate Cancer (OMPC)
The purpose of this study is to evaluate the efficacy and safety of lutetium (177Lu) vipivotide tetraxetan (AAA617) in p…
Fayetteville, United States Est. completion Apr 25, 2028